SCHEMBL2245977

SCHEMBL2245977

CCN(CC)S(=O)(=O)c1cccc(-c2nc(N)c3cc(-c4c(Cl)cccc4Cl)c(=O)n(OC)c3n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ GFER P55789 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 7/20 0.36
▸ GAA P10253 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ APOBEC3G Q9HC16 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ TSHR P16473 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MPI P34949 1/20 0.34
▸ PHOSPHO1 Q8TCT1 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ FGFR1 P11362 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ FGFR2 P21802 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245930 0.88 RIPK2 (0.41) EGFRFGFR1SRCFGFR2FGFR4
SCHEMBL2245947 0.87 BRD4 (0.42) EGFRFGFR1SRCFGFR2FGFR4
SCHEMBL2359361 0.85 NR1H2 (0.37) EGFRFGFR1SRCFGFR2FGFR4
SCHEMBL2245139 0.83 BRD4 (0.45) ALDH1A1GAAFGFR1
SCHEMBL2253187 0.82 BRD4 (0.45) LMNAKDM4EALDH1A1GAARXFP1
SCHEMBL2246715 0.81 FGFR1 (0.39) EGFRFGFR1SRCFGFR2FGFR4
SCHEMBL2252104 0.80 HSP90AA1 (0.43) LMNAKDM4EALDH1A1MAPTTSHR
SCHEMBL2245153 0.80 SRC (0.36) EGFRFGFR1SRCFGFR2FGFR4
SCHEMBL2249833 0.79 SRC (0.40) MEN1KMT2AEGFRFGFR1SRC
SCHEMBL2246030 0.78 FGFR1 (0.38) EGFRFGFR1SRCFGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163223-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US claimed
US-8518958-B2 Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors FORMA THERAPEUTICS, INC. (US) 2013-08-27 — — US claimed
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS Valo Health, LLC 2011-08-18 — — US claimed
EP-2084159-A1 PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC Biotech Inc. (US) 2009-08-05 — — EP claimed
WO-2008047307-A1 PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC BIOTECH INC. (US) 2008-04-24 — — WO claimed
US-20140163007-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed
US-8518958-B2 Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors FORMA THERAPEUTICS, INC. (US) 2013-08-27 — — US disclosed
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS Valo Health, LLC 2011-08-18 — — US disclosed
EP-2084159-A1 PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC Biotech Inc. (US) 2009-08-05 — — EP disclosed
WO-2008150260-A1 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS GPC BIOTECH, INC. (US) 2008-12-11 — — WO disclosed
WO-2008047307-A1 PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS GPC BIOTECH INC. (US) 2008-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163007-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163005-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163004-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20140163223-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 LMNA 2689/4885NPC1 4272/4885RAB9A 2725/4885
US-20110201594-A1 PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS DCK, PDXK, TK1 LMNA 2923/4885NPC1 4226/4885RAB9A 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback